🇺🇸 FDA
Pipeline program

IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

IOB-022/KN-D38

Phase 2 small_molecule active

Quick answer

IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).

Program details

Company
IO Biotech
Indication
Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials